CALLUNA PHARMA AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO: MW
Mark William-Semrau Gaffney1976
Chairman of the board: MF
Mark Frederick Altmeyer1960
Years since formation: 2 years; since Oct 14, 2023
Type: Limited company
VAT registered: Yes
Number of employees: 9

Ownership

Number of shares and share classes: 74,167,000; 3 share classes
Total number of shareholders: 6; 3 companies, 3 persons
Belongs to group of

Financials

Total operating income 2024: 26,904,988; NOK
Annual total result 2024: -11,910,670; NOK
Total equity 2024: 769,267,140; NOK

Last update: Aug 14, 2025

Management

Management / administration

Name	Role	Shares
MW Mark William-Semrau Gaffney 1976	Managing Director/CEO	-

Board

Name	Role	Shares
SS Susanne Stuffers 1981	Board Member	-
FA Farzad Abdi-Dezfuli 1963	Board Member	-
AB Antoine Boulanger Piette 1990	Board Member	-
MB Marco Boorsma 1974	Board Member	-
JJ Johannes Jacob Pieter Kastelein 1954 Resigned	Board Member	-
MF Mark Frederick Altmeyer 1960	Chairman	-
MW Mark William-Semrau Gaffney 1976	Board Member	-

Others

Name	Role	Shares
D DYNAMIK SMART ACCOUNTING AS	Accountant	-
B BJØRGVIN REVISJON AS	Auditor	-

Last update: Apr 10, 2025

Ownership

Company shareholders

Name	Share class	Total number of shares	Share
C CALLUNA PHARMA POOLCO AS	Ordinary shares	33,867,000	45.66 %
FC Forbion Capital Fund Iv Cooperatief	Ordinary shares	27,422,185	36.97 %
FI Forcal I Investment Fund	Ordinary shares	8,300,000	11.19 %
SA Stitching Administratiekantoor Oxit	Extraordinary shares	3,463,451	4.67 %
C CALLUNA PHARMA POOLCO AS	Extraordinary shares	687,056	0.93 %
C CALLUNA PHARMA POOLCO AS	J-shares	427,308	0.58 %

Shares owned by the CALLUNA PHARMA AS

Name	Share class	Total number of shares	Share
A ARXX THERAPEUTICS AS	Ordinary shares	26,043,511	100 %

Last update: Jun 2, 2025

Group structure

CALLUNA PHARMA AS
Total operating income 2024: NOK 26,904,988
Operating profit 2024: NOK -26,638,063
Employees: 9

Financials

in NOK

Summary

Year	2023
Total operating income	26,904,988
Annual Total Result	-11,910,670
Total assets	853,584,265
Total liabilities	84,317,125
Total equity	769,267,140

P&L

Year	2023
Total operating income	26,904,988
Total operating costs	53,543,051
Operating result	-26,638,063
Financial income/costs	14,727,394
Profit before tax	-11,910,670
Total tax & extraordinary income/cost	0
Annual Total Result	-11,910,670

Balance overview

Year	2023
Total fixed assets	645,315,226
Total current assets	208,269,039
Total assets	853,584,265
Short term debt	84,317,125
Long term debt	0
Total liabilities	84,317,125
Contributed capital	769,267,140
Retained earnings	0
Total equity	769,267,140
Total equity and liabilities	853,584,265

CALLUNA PHARMA AS932 255 189